EMPA-KIDNEY. A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease

Awarded By

  • Boehringer Ingelheim/University of Oxford

Contributors

Start/End

  • 2017